If that is the case, enzalutamide and other newly generation of AR antagonists such as apalutamide could provide superior GBM control benefit compared to older generation drugs or antagonists/agonists of gonadotropin-releasing hormone (GnRH) that suppress androgen production, as having been demonstrated by a phase III clinical trial on metastatic prostate cancer (84). This evidence concerns the gene AR and glioblastoma.